WAM
BXRX

Warberg Asset Management’s Baudax Bio, Inc. Common Stock BXRX Stock Holding History

Warberg Asset Management’s Portfolio BXRX Stock Details BXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-6,750
Closed -$66K – 353
2022
Q3 		$66K Buy
6,750
+5,887
+682% +$137K 0.01% 165
2022
Q2 		$29K Hold
863
– – 0.01% 170
2022
Q1 		$61K Buy
+863
New +$159K 0.01% 149

Other funds holding BXRX

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
EDRH
Edmond de Rothschild Holding Chambesy, Switzerland $6.91B AUM 19.7% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SN
Sittner & Nelson Eugene, Oregon $274M AUM 22.46% 1-Year Est. Return

Warberg Asset Management's BXRX Position: Q4 2022 in Review

Warberg Asset Management sold out of Baudax Bio, Inc. Common Stock (BXRX) in Q4 2022, closing a stake of 6,750 shares — an estimated $66K sold.

Warberg Asset Management first reported a position in BXRX in Q1 2022 and held it in 3 quarters. The position peaked at $66K in Q3 2022. 10 funds tracked by Wall St. Rank hold BXRX as of Q4 2022.

  • Warberg Asset Management reported no remaining Baudax Bio, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Warberg Asset Management sold 6,750 Baudax Bio, Inc. Common Stock shares in Q4 2022, an estimated $66K.
  • Warberg Asset Management first reported a position in Baudax Bio, Inc. Common Stock in Q1 2022 and held it in 3 quarters.
  • Warberg Asset Management's Baudax Bio, Inc. Common Stock position peaked at $66K in Q3 2022.
  • 10 funds tracked by Wall St. Rank held Baudax Bio, Inc. Common Stock as of Q4 2022.

Based on Warberg Asset Management's 13F filing for Q4 2022, filed 13 Feb 2023.